Page last updated: 2024-11-13

3-hydroxyisovalerylcarnitine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-hydroxyisovalerylcarnitine : An O-acylcarnitine having 3-hydroxyisovaleryl as the acyl substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID71464474
CHEBI ID73027
SCHEMBL ID288247
MeSH IDM0257794

Synonyms (10)

Synonym
CHEBI:73027
3-hydroxyisovalerylcarnitine
3-[(3-hydroxy-3-methylbutanoyl)oxy]-4-(trimethylammonio)butanoate
3-[(3-hydroxy-3-methylbutanoyl)oxy]-4-(trimethylazaniumyl)butanoate
SCHEMBL288247
LMFA07070041
hydroxyisovaleroyl-d3 carnitine
3-((3-hydroxy-3-methylbutanoyl)oxy)-4-(trimethylammonio)butanoate
Q27105004
STARBLD0015240
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
O-acylcarnitineAny carboxylic ester obtained by the O-acylation of carnitine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (7.69)18.2507
2000's3 (11.54)29.6817
2010's20 (76.92)24.3611
2020's1 (3.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.74 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index5.11 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (7.69%)5.53%
Reviews0 (0.00%)6.00%
Case Studies3 (11.54%)4.05%
Observational0 (0.00%)0.25%
Other21 (80.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]